Search the Newsreel

Mustang Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Mustang Bio, Inc. announced its financial results for the second quarter and first six months ended June 30, 2026. For the second quarter, the company reported a net loss of $1.07 million, an increase from $0.762 million in the prior year, with a basic …

Standard BioTools Inc. (LAB) Stock Price, News, Quote & History

This article provides comprehensive financial information for Standard BioTools Inc. (LAB), including its current stock price, historical data, and analyst ratings. It details the company's overview, its segments in proteomics and genomics, key products like the SomaScan platform and CyTOF technology, and financial performance …

Standard BioTools Reports Second Quarter 2026 Financial Results

Standard BioTools Inc. announced its financial results for the second quarter of 2026, reporting $20.1 million in revenue and an 84% improvement in adjusted EBITDA year-over-year. The company is progressing with its merger with Treeline Biosciences, anticipated to close before year-end 2026, and has …

Morgan Stanley Lowers Advantage Solutions (NASDAQ:ADV) Price Target to $34.00

Morgan Stanley has lowered its price target for Advantage Solutions (NASDAQ:ADV) to $34.00 from $35.00, while maintaining an "equal weight" rating, suggesting a potential upside of 46.93%. Despite missing quarterly EPS estimates significantly, the company's revenue slightly exceeded expectations. Analyst sentiment remains mixed, with …

Stanley Black & Decker Inc. stock underperforms Thursday when compared to competitors

Stanley Black & Decker Inc. (SWK) stock fell by 2.16% on Thursday, closing at $101.04. This underperformance occurred during a generally difficult trading session, with the S&P 500 Index declining by 0.18% and the Dow Jones Industrial Average falling by 0.85%. The decline ended …

Billion-Dollar Morgan Stanley Team Jumps to RBC in Virginia

A billion-dollar team, The Sexton Group, led by Mary M. Sexton and Erik M. Knobl, has moved from Morgan Stanley to RBC Wealth Management in Tysons, Virginia. The team, which managed $1 billion in assets, joined RBC on Tuesday, August 4, 2026, marking another …

AppLovin's Q2 Miss Reflects Execution Issue, Not Structural Headwinds, Morgan Stanley Says

Morgan Stanley suggests that AppLovin's Q2 earnings miss is due to a short-term execution problem rather than larger structural issues affecting the company. The article, however, is a premium piece, requiring a subscription to read the full details.

Standex International About To Put More Money In Your Pocket (SXI)

Looking at the universe of stocks we cover at Dividend Channel, on 8/7/26, Standex International Corp. (Symbol: SXI) will trade ex-dividend, for its quarterly dividend of $0.34, payable on 8/21/26. As a percentage of SXI's recent stock price of $328.10, this dividend works out …

Morgan Stanley reiterates Ross Stores stock rating with $231 target By Investing.com

Morgan Stanley has reiterated an Equalweight rating on Ross Stores (NASDAQ: ROST) with a price target of $231.00. The stock is currently trading above this target at $254.76, near its 52-week high, and InvestingPro analysis suggests it is overvalued despite a "GREAT" financial health …

Hedge fund Jain Global hired Morgan Stanley's head of high yield trading in London

Jain Global, a hedge fund founded by Bobby Jain, has hired Jon Stead, Morgan Stanley's former head of high yield trading in London. Stead is expected to help establish a new European high yield trading business for Jain Global, which recently began managing money …

Standard Chartered: Attractive Exposure To Emerging Markets Despite Higher Loan Loss Provisions

VSTD: Vestand Inc. - Price & Consenus Chart

LifeStance Health surges on strong Q2 beat and raised outlook

LifeStance Health Group (NASDAQ:LFST) reported stronger-than-expected second-quarter results and raised its full-year guidance, leading to an 11.7% surge in shares. The company posted adjusted EPS of $0.06 and revenue of $435.4 million, exceeding analyst estimates, and saw a significant increase in net income and …

Figma's AI-Led Revenue Growth Accompanied by Delayed Profitability, Morgan Stanley Says

Morgan Stanley reports that Figma is experiencing accelerated revenue growth, driven by the monetization of its AI credits. However, this growth is coupled with a delay in achieving profitability for the company. The full article content is behind a premium paywall.

LifeStance Health Group (LFST) Tops Q2 Earnings and Revenue Estimates

LifeStance Health Group (LFST) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …

Morgan Stanley Adjusts PT on International Flavors & Fragrances to $100 From $95, Keeps Overweight Rating

Morgan Stanley has increased its price target for International Flavors & Fragrances (IFF) to $100 from $95, while maintaining an "Overweight" rating on the stock. This adjustment follows several recent announcements from IFF, including its Q2 2026 earnings call, a trimming of its annual …

Morgan Stanley Adjusts Price Target on Newell Brands to $5.75 From $3.50, Maintains Underweight Rating

Morgan Stanley has increased its price target for Newell Brands (NWL) to $5.75 from $3.50, while maintaining an "Underweight" rating on the stock. This adjustment reflects a revised outlook from the analyst firm. The article also lists other recent news and analyst actions related …

Morgan Stanley Adjusts PT on TransDigm Group to $1,400 From $1,345, Maintains Equalweight Rating

Morgan Stanley has increased its price target for TransDigm Group (TDG) to $1,400 from $1,345, while maintaining an "Equalweight" rating on the stock. This adjustment reflects the firm's updated outlook on the aerospace and defense company. The article also mentions recent analyst updates from …

Morgan Stanley Adjusts PT on BrightView Holdings to $12.50 From $14, Maintains Equalweight Rating

Morgan Stanley has lowered its price target for BrightView Holdings (BV) to $12.50 from $14, while keeping an Equalweight rating on the stock. This adjustment comes after BrightView Holdings reported its Q3 2026 earnings, posting an adjusted EPS of $0.17, which was below FactSet's …

Earnings Flash (LFST) LifeStance Health Posts Q2 EPS $0.06, vs. FactSet Est of $0.04

LifeStance Health Group (LFST) reported its Q2 EPS at $0.06, surpassing the FactSet estimate of $0.04. The company also announced an equity buyback of $100 million worth of its shares and raised its earnings guidance for the fiscal year 2026, alongside providing Q3 2026 …

LifeStance board approves up to $100 million share buyback

LifeStance Health Group (Nasdaq: LFST) reported strong Q2 2026 financial results with revenue up 26% year-over-year to $435.4 million and net income turning positive at $23.6 million. The company raised its full-year 2026 guidance for revenue, Center Margin, and Adjusted EBITDA. Additionally, LifeStance announced …

LifeStance Health Group (NASDAQ:LFST) Reports Strong Q2 CY2026, Guides for Strong Full-Year Sales

LifeStance Health Group (NASDAQ:LFST) reported strong Q2 CY2026 results, surpassing Wall Street's revenue and EPS expectations. The company's sales rose 26.1% year-on-year to $435.4 million, and its GAAP profit was $0.06 per share. LifeStance also raised its full-year revenue and EBITDA guidance, indicating a …

LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook

LifeStance Health Group, Inc. announced strong financial results for the second quarter of 2026, with revenue increasing by 26% to $435.4 million and net income reaching $23.6 million. The company raised its full-year 2026 outlook for revenue, Center Margin, and Adjusted EBITDA, and approved …

Morgan Stanley Adjusts Price Target on Criteo to $25 From $29, Maintains Equalweight Rating

Morgan Stanley has revised its price target for Criteo (CRTO) shares down to $25 from the previous $29, while keeping an "Equalweight" rating on the stock. This adjustment reflects the firm's updated outlook for the digital performance marketing company. The news was published on …

Standard Engineering Technology Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Mustang Bio Inc (MBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Mustang Bio Inc (MBIO), noting that no earnings forecast score is currently available for the company. It highlights the average score for the Biotechnology & Medical Research industry, which is 8.10, and includes a peer comparison of …

STANDARD BIOTOOLS INC. Q2 2026: Revenue $20.1M, EPS $(0.07) — 10-Q Summary

STANDARD BIOTOOLS INC. reported its Q2 2026 results, showing revenue of $20.1M and a diluted loss per share of $(0.07), which indicates an improvement compared to the previous year. Key highlights include an announced merger with Treeline Biosciences, the divestiture of the SomaScan business …

IBM Aktie: Morgan Stanley senkt Ziel auf 190 Dollar

Morgan Stanley Direct Lending Fund (MSDL) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

StandardAero (NYSE:SARO) Posts Earnings Results, Beats Estimates By $0.08 EPS

LifeStance Health Group (LFST) Earnings Date and Reports 2026 $LFST

Projeções de Resultados: Morgan Stanley Direct Lending Fund (MSDL) — LPA e Crescimento de Receita

Standard Engineering Technology makes Q1FY27 earnings call recording available

StandardAero, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:SARO) 2026-08-06

StandardAero (NYSE: SARO) lifts 2026 outlook after margin gains and Q2 earnings jump

Morgan Stanley Direct Lending Fund portfolio: 229 companies, 36 industries